

Trajan Scientific and Medical

Global Corporate Headquarters 7 Argent Place, Ringwood Victoria 3134, Australia Tel: +61 (0) 3 9837 4200 www.trajanscimed.com

Trajan Group Holdings Limited ACN 152 617 706

ASX RELEASE

Trajan FY23 Half Year Results and Investor Webcast Notification

3 February 2023 – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan** or **the Company**) today advises it will release its Half Year Results for the Financial Year ending 30 June 2023 (FY23), on Monday 27 February 2023.

Investors are invited to join a live webcast and Q&A hosted by Trajan CEO and Managing Director, Stephen Tomisich and Chief Financial Officer Alister Hodges, on Monday 27 February 2023 at 9:30am Australian Eastern Daylight Time (AEDT). Investors are invited to submit questions beforehand via the webinar registration page.

To register for the webcast, please follow this link: https://trajanscimed.zoom.us/webinar/register/WN jTrFwvyhQEOTGipIURdkDA

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited.

END

Contact:

Investors
Rebecca Wilson
WE Communications
investorrelations@trajanscimed.com

Media
Amy Miller
WE Communications
amymi@we-worldwide.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 680 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.